Literature DB >> 25477335

H3K9 histone methyltransferase, KMT1E/SETDB1, cooperates with the SMAD2/3 pathway to suppress lung cancer metastasis.

Pei-Chun Wu1, Jeng-Wei Lu2, Jer-Yen Yang3, I-Hsuan Lin1, Da-Liang Ou4, Yu-Hsiang Lin1, Kuan-Hsien Chou1, Wen-Feng Huang1, Wan-Ping Wang5, Yih-Leh Huang6, Chiun Hsu4, Liang-In Lin7, Yueh-Min Lin8, C-K James Shen9, Tsai-Yu Tzeng10.   

Abstract

Aberrant histone methylation is a frequent event during tumor development and progression. KMT1E (also known as SETDB1) is a histone H3K9 methyltransferase that contributes to epigenetic silencing of both oncogenes and tumor suppressor genes in cancer cells. In this report, we demonstrate that KMT1E acts as a metastasis suppressor that is strongly downregulated in highly metastatic lung cancer cells. Restoring KMT1E expression in this setting suppressed filopodia formation, migration, and invasive behavior. Conversely, loss of KMT1E in lung cancer cells with limited metastatic potential promoted migration in vitro and restored metastatic prowess in vivo. Mechanistic investigations indicated that KMT1E cooperates with the TGFβ-regulated complex SMAD2/3 to repress metastasis through ANXA2. Together, our findings defined an essential role for the KMT1E/SMAD2/3 repressor complex in TGFβ-mediated lung cancer metastasis. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25477335     DOI: 10.1158/0008-5472.CAN-13-3572

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  24 in total

Review 1.  Epigenetic regulation of epithelial-mesenchymal transition.

Authors:  Lidong Sun; Jia Fang
Journal:  Cell Mol Life Sci       Date:  2016-07-08       Impact factor: 9.261

Review 2.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Authors:  Yuan Cheng; Cai He; Manni Wang; Xuelei Ma; Fei Mo; Shengyong Yang; Junhong Han; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

Review 3.  Zebrafish Discoveries in Cancer Epigenetics.

Authors:  Yelena Chernyavskaya; Brandon Kent; Kirsten C Sadler
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

Review 4.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Authors:  Yuan Cheng; Cai He; Manni Wang; Xuelei Ma; Fei Mo; Shengyong Yang; Junhong Han; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

5.  Smad3-mediated recruitment of the methyltransferase SETDB1/ESET controls Snail1 expression and epithelial-mesenchymal transition.

Authors:  Dan Du; Yoko Katsuno; Dominique Meyer; Erine H Budi; Si-Han Chen; Hartmut Koeppen; Hongjun Wang; Rosemary J Akhurst; Rik Derynck
Journal:  EMBO Rep       Date:  2017-12-12       Impact factor: 8.807

6.  Histone H3K9 methyltransferase SETDB1 augments invadopodia formation to promote tumor metastasis.

Authors:  Shuhei Ueshima; Jia Fang
Journal:  Oncogene       Date:  2022-05-11       Impact factor: 9.867

7.  JARID1D Is a Suppressor and Prognostic Marker of Prostate Cancer Invasion and Metastasis.

Authors:  Na Li; Shilpa S Dhar; Tsai-Yu Chen; Pu-Yeh Kan; Yongkun Wei; Jae-Hwan Kim; Chia-Hsin Chan; Hui-Kuan Lin; Mien-Chie Hung; Min Gyu Lee
Journal:  Cancer Res       Date:  2016-01-08       Impact factor: 12.701

8.  Variants of ubiquitin-specific peptidase 24 play a crucial role in lung cancer malignancy.

Authors:  Y-C Wang; S-A Wang; P-H Chen; T-I Hsu; W-B Yang; Y-P Chuang; W-C Su; H-J Liaw; W-C Chang; J-J Hung
Journal:  Oncogene       Date:  2015-11-16       Impact factor: 9.867

Review 9.  Insight into the multi-faceted role of the SUV family of H3K9 methyltransferases in carcinogenesis and cancer progression.

Authors:  Nirmalya Saha; Andrew G Muntean
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-12-26       Impact factor: 10.680

Review 10.  The roles of epigenetics in cancer progression and metastasis.

Authors:  Jocelyn F Chen; Qin Yan
Journal:  Biochem J       Date:  2021-09-17       Impact factor: 3.766

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.